The Experimental Therapeutics Centre (ETC) was set up by the Agency of Science, Technology & Research (A STAR) in 2007 as a centre of excellence to advance and accelerate drug development in Singapore.
Our primary mission is to guide early stage scientific discoveries towards proof-of-concept in man and translate scientific discoveries into diagnostics and research tools in order to serve unmet medical needs.
We provide a collaborative public-private partnership framework to translate early stage discoveries into drug candidates, diagnostics and innovative research tools in collaboration with academic and industrial partners.
In the process, we aim to develop technology platforms that can be utilized by the R&D community in Singapore, and provide education, mentoring and support for staff, scientists, clinicians and students who are interested in drug development.
Situated within the thriving Biopolis campus where research institutes are co-located with pharmaceutical and biotech companies and in close proximity to universities and major healthcare institutions, ETC is well-positioned to tap on synergies for multi-disciplinary research and harness the tremendous capability of the R&D community here to develop exciting new products that advance human healthcare, benefit those who have generated the ideas and the institutions from which they originate, and create value for Singapore.
ETC is a member of Singapore’s Biopolis community which, housing more than 2,500 scientists, provides an extensive source of know-how and technologies at our doorstep.
In our own facility, we possess the full range of drug discovery capabilities, including assay development, high throughput screening, medicinal chemistry and ADME/toxicology. These capabilities allow us to identify drug hits and leads, and develop them to the preclinical candidate stage in-house. In collaboration with expert partners in Singapore, we are set to complete Investigational New Drug (IND)-enabling manufacturing, pre-clinical toxicology studies and IND filing. In addition, supported by local Investigational Medicine Units, ETC is ready for First-in-Human clinical trials.